563 related articles for article (PubMed ID: 18953278)
1. The relationship between erectile dysfunction and cardiovascular disease. Part II: The role of PDE-5 inhibition in sexual dysfunction and cardiovascular disease.
Kapur V; Chien CV; Fuess JE; Schwarz ER
Rev Cardiovasc Med; 2008; 9(3):187-95. PubMed ID: 18953278
[TBL] [Abstract][Full Text] [Related]
2. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibition in chronic heart failure and pulmonary hypertension.
Patel MD; Katz SD
Am J Cardiol; 2005 Dec; 96(12B):47M-51M. PubMed ID: 16387567
[TBL] [Abstract][Full Text] [Related]
5. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems.
Schwarz ER; Kapur V; Rodriguez J; Rastogi S; Rosanio S
Int J Impot Res; 2007; 19(2):139-48. PubMed ID: 16761012
[TBL] [Abstract][Full Text] [Related]
6. PDE5 inhibitors beyond erectile dysfunction.
Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
[TBL] [Abstract][Full Text] [Related]
7. [Novel indications for phosphodiesterase type 5 inhibitors].
Rosenkranz S; Caglayan E; Erdmann E
Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
[TBL] [Abstract][Full Text] [Related]
8. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
Kostis JB; Jackson G; Rosen R; Barrett-Connor E; Billups K; Burnett AL; Carson C; Cheitlin M; Debusk R; Fonseca V; Ganz P; Goldstein I; Guay A; Hatzichristou D; Hollander JE; Hutter A; Katz S; Kloner RA; Mittleman M; Montorsi F; Montorsi P; Nehra A; Sadovsky R; Shabsigh R
Am J Cardiol; 2005 Jul; 96(2):313-21. PubMed ID: 16018863
[TBL] [Abstract][Full Text] [Related]
9. Nonarteritic anterior ischemic optic neuropathy with PDE-5 inhibitors for erectile dysfunction.
Thurtell MJ; Tomsak RL
Int J Impot Res; 2008; 20(6):537-43. PubMed ID: 18528398
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 inhibitors for erectile dysfunction.
Carson CC; Lue TF
BJU Int; 2005 Aug; 96(3):257-80. PubMed ID: 16042713
[TBL] [Abstract][Full Text] [Related]
11. [Experience of using three phosphodiesterase type 5 inhibitors in the same period for the treatment of erectile dysfunction].
Zhang SX; Gao P
Zhonghua Nan Ke Xue; 2007 Mar; 13(3):226-8. PubMed ID: 17393785
[TBL] [Abstract][Full Text] [Related]
12. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors.
Jackson G
Am J Cardiol; 2005 Dec; 96(12B):32M-36M. PubMed ID: 16387564
[TBL] [Abstract][Full Text] [Related]
14. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors.
Bella AJ; Brant WO; Lue TF; Brock GB
Can J Urol; 2006 Oct; 13(5):3233-8. PubMed ID: 17076943
[TBL] [Abstract][Full Text] [Related]
15. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
[TBL] [Abstract][Full Text] [Related]
16. Sildenafil: emerging cardiovascular indications.
Raja SG; Nayak SH
Ann Thorac Surg; 2004 Oct; 78(4):1496-506. PubMed ID: 15464535
[TBL] [Abstract][Full Text] [Related]
17. Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
Kukreja RC; Ockaili R; Salloum F; Yin C; Hawkins J; Das A; Xi L
J Mol Cell Cardiol; 2004 Feb; 36(2):165-73. PubMed ID: 14871543
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction.
Axilrod AC
Curr Med Res Opin; 2007 Dec; 23(12):3189-98. PubMed ID: 17991309
[TBL] [Abstract][Full Text] [Related]
19. Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?
Carter JE
J Neurol Sci; 2007 Nov; 262(1-2):89-97. PubMed ID: 17706972
[TBL] [Abstract][Full Text] [Related]
20. Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Park JW; Leithäuser B; Jung F
Clin Hemorheol Microcirc; 2008; 39(1-4):323-8. PubMed ID: 18503141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
